Answers are grounded in this paper and cite their sources.
Remdesivir significantly reduced the early mortality rate in COVID-19 patients with comorbid hemato-oncological disease, which emphasizes the need to administer this agent to immunosuppressed patients.
No takes yet. Share an insight, caveat, or question.
Aksak‐Wąs et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: